Implementation of a Pragmatic Trial of Whole Health Team vs. Primary Care Group Education to Promote Non-Pharmacological Strategies to Improve Pain, Function and Quality of Life in Veterans

实施整体健康团队与初级保健团体教育的务实试验,以促进非药物策略,改善退伍军人的疼痛、功能和生活质量

基本信息

  • 批准号:
    10533361
  • 负责人:
  • 金额:
    $ 129.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-01-20 至 2024-12-31
  • 项目状态:
    已结题

项目摘要

7. PROJECT SUMARY ABSTRACT The overarching goal of this Pain Management Collaboratory Demonstration project is to implement a new Whole Health paradigm for chronic pain care, emphasizing non-pharmacologic pain self-management that reduces pain symptoms and improves overall functioning and quality of life in veterans. The objective of this UG3/UH3 proposal is to develop and pilot components that will be used to support a pragmatic implementation-effectiveness trial of two pain care delivery approaches that differ in structure, comprehensiveness, and intensity. During the trial phase, over 600 veterans across 4 geographically diverse VA health care facilities with moderate to severe chronic pain (irrespective of chronic opioid therapy) will be randomized to receive an intensive Whole Health Team (WHT) versus a less intensive usual care Primary Care Group Education (PC-GE) approach. All enrolled veterans will be followed for 12 months. In preparation for the trial, specific aims of the 2-year UG3 phase include: UG3 Aim 1: to use an evidence-based implementation framework to conduct a formative evaluation that engages trial stakeholders at the 4 VA enrolling sites, solicits feedback on specific trial components, and identifies barriers to and facilitators of trial implementation, and UG3 Aim 2: to use stakeholder input to adapt, pilot and refine key components for the successful implementation of the pragmatic trial including: non-pharmacologic multi-modal pain self- management education for patients and providers, point-of-care data collection applications, patient reported measures sensitive to whole health interventions, wrist-worn activity monitors, and web/mobile applications to support in vivo monitoring of activity and pain and to provide tools for pain self-management. Assuming transition to the 4-year trial UH3 phase, we will implement these components refined in the UG3 phase. In UH3 Aim 1 we will conduct a 12-month pragmatic effectiveness trial to test whether veterans with moderate to severe chronic pain randomized to receive the Whole Health Team (WHT) intervention are more likely than those receiving Primary Care Group Education (PC-GE) to: H1: Experience improved pain severity and interference, functioning and quality of life (primary outcome); H2: Decrease use of higher risk pain medications, including opioids, or high risk combinations (secondary); H3: Engage in a greater number of non- pharmacological pain management activities (secondary); H4: Experience improved comorbid mental health symptoms, including sleep problems and suicidality. UH3 Aim 2 is to conduct a process evaluation and budget impact analysis of the implementation of the two interventions to support the development of an implementation toolkit for scaling and dissemination. Results of this UG3/UH3 Pain Management Collaboratory Demonstration project will contribute to the overall mission of the NIH/VA/DoD initiative to build national-level infrastructure that supports non-pharmacologic pain management in veterans and military service personnel.
7.项目摘要 这个疼痛管理合作实验室示范项目的总体目标是实施一个新的 慢性疼痛护理的整体健康模式,强调非药物疼痛自我管理, 减轻疼痛症状,改善退伍军人的整体功能和生活质量。的目的 UG 3/UH 3建议是开发和试验将用于支持务实的 两种不同结构疼痛护理提供方法的实施效果试验, 全面性和强度。在试验阶段,来自4个不同地理位置的600多名退伍军人 患有中度至重度慢性疼痛的VA医疗保健机构(无论是否接受慢性阿片类药物治疗)将 随机接受强化整体健康团队(WHT)与不太强化的常规护理初级 护理小组教育(PC-GE)方法。所有登记的退伍军人将被跟踪12个月。在制备 对于试验,2年UG 3阶段的具体目标包括:UG 3目标1:使用基于证据的 实施框架,以进行形成性评价,让4VA的试验利益相关者参与 招募研究中心,征求对特定试验组成部分的反馈,并确定试验的障碍和促进因素 实施,以及UG 3目标2:利用利益相关者的意见来调整、试点和完善 成功实施的务实试验,包括:非药物多模式疼痛自我, 针对患者和提供者的管理教育、床旁数据收集应用程序、患者报告 对整体健康干预、腕戴式活动监测器和网络/移动的应用程序敏感的措施, 支持活动和疼痛的体内监测,并提供疼痛自我管理的工具。假设 过渡到为期4年的试验UH 3阶段,我们将实施在UG 3阶段改进的这些组件。在UH 3 目标1:我们将进行一项为期12个月的务实有效性试验,以测试中度至中度 随机接受全健康团队(WHT)干预的严重慢性疼痛患者比 接受初级保健小组教育(PC-GE)的患者:H1:疼痛严重程度改善, 干预、功能和生活质量(主要结局); H2:减少使用高风险疼痛 药物,包括阿片类药物,或高风险组合(次要); H3:参与更多的非药物治疗, 药物性疼痛管理活动(次要); H4:共病心理健康状况改善 症状,包括睡眠问题和自杀倾向。UH 3目标2是进行过程评估和预算 对执行两项干预措施的影响进行分析,以支持制定一项 用于扩展和传播的实施工具包。此UG 3/UH 3疼痛管理合作实验室的结果 示范项目将有助于NIH/VA/DoD倡议的总体使命, 基础设施,支持退伍军人和军事服务人员的非药物疼痛管理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WILLIAM C BECKER其他文献

WILLIAM C BECKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WILLIAM C BECKER', 18)}}的其他基金

Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy - Yale Resource Center (MIRHIQL-YRC)
多层次干预措施可减少长期阿片类药物治疗患者的伤害并提高其生活质量 - 耶鲁大学资源中心 (MIRHIQL-YRC)
  • 批准号:
    10722768
  • 财政年份:
    2023
  • 资助金额:
    $ 129.84万
  • 项目类别:
HD2A Research Adoption Support Center (RASC)
HD2A 研究采用支持中心 (RASC)
  • 批准号:
    10708980
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
Role of Non-pharmacological Pain Treatments in Safe and Effective Opioid Tapering in Chronic Pain
非药物疼痛治疗在安全有效地逐渐减少慢性疼痛中阿片类药物的作用
  • 批准号:
    10620195
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
HD2A RASC - Pain Implementation Support Core
HD2A RASC - 疼痛实施支持核心
  • 批准号:
    10596438
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
HD2A Research Adoption Support Center (RASC)
HD2A 研究采用支持中心 (RASC)
  • 批准号:
    10596435
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
HD2A RASC - Pain Implementation Support Core
HD2A RASC - 疼痛实施支持核心
  • 批准号:
    10708984
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers
HEAL 计划:慢性疼痛和 OUD 整体康复综合管理 (IMPOWR):研究中心
  • 批准号:
    10876682
  • 财政年份:
    2021
  • 资助金额:
    $ 129.84万
  • 项目类别:
HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers
HEAL 计划:慢性疼痛和 OUD 整体康复综合管理 (IMPOWR):研究中心
  • 批准号:
    10652027
  • 财政年份:
    2021
  • 资助金额:
    $ 129.84万
  • 项目类别:
HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers
HEAL 计划:慢性疼痛和 OUD 整体康复综合管理 (IMPOWR):研究中心
  • 批准号:
    10378910
  • 财政年份:
    2021
  • 资助金额:
    $ 129.84万
  • 项目类别:
Implementation of a Pragmatic Trial of Whole Health Team vs. Primary Care Group Education to Promote Non-Pharmacological Strategies to Improve Pain, Function and Quality of Life in Veterans
实施整体健康团队与初级保健团体教育的务实试验,以促进非药物策略,改善退伍军人的疼痛、功能和生活质量
  • 批准号:
    10090568
  • 财政年份:
    2020
  • 资助金额:
    $ 129.84万
  • 项目类别:

相似海外基金

Planning Study for the Development of Sigma 2 ligands as Analgesics
Sigma 2 配体镇痛药开发规划研究
  • 批准号:
    10641500
  • 财政年份:
    2023
  • 资助金额:
    $ 129.84万
  • 项目类别:
Designing and validating optimal nonaddictive analgesics using the CANDO paradigm
使用 CANDO 范式设计和验证最佳的非成瘾性镇痛药
  • 批准号:
    10485593
  • 财政年份:
    2023
  • 资助金额:
    $ 129.84万
  • 项目类别:
Identification of botanical hHv1 channel blockers as analgesics for neuropathic pain
植物 hHv1 通道阻滞剂作为神经性疼痛镇痛药的鉴定
  • 批准号:
    10728526
  • 财政年份:
    2023
  • 资助金额:
    $ 129.84万
  • 项目类别:
Development of LPA5 Antagonists as Analgesics
LPA5 拮抗剂镇痛药的开发
  • 批准号:
    10638278
  • 财政年份:
    2023
  • 资助金额:
    $ 129.84万
  • 项目类别:
Designed Multiple Ligands as Non-opioid Analgesics for Treating Chronic Pain
设计多种配体作为非阿片类镇痛药,用于治疗慢性疼痛
  • 批准号:
    10621646
  • 财政年份:
    2023
  • 资助金额:
    $ 129.84万
  • 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
  • 批准号:
    10425794
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
Elucidation of the mechanism of pain suppression by exercise and development of new analgesics
阐明运动镇痛机制及开发新型镇痛药
  • 批准号:
    22K19602
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics
大麻素 CB1 受体变构靶向开发非成瘾性小分子镇痛药
  • 批准号:
    10512672
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
A novel clinically-relevant mouse model of chronic overlapping pain conditions for screening analgesics
用于筛选镇痛药的新型临床相关慢性重叠疼痛小鼠模型
  • 批准号:
    10821681
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
Single-administration microneedles with controlled sustained release of non-opioid analgesics to treat osteoarthritis pain
单次给药微针控制缓释非阿片类镇痛药治疗骨关节炎疼痛
  • 批准号:
    10721752
  • 财政年份:
    2022
  • 资助金额:
    $ 129.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了